
## Andrew Evans

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11597179/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1295-1305.	2.3	10
2	Quantifying the impact of upper limb tremor on the quality of life of people with multiple sclerosis: a comparison between the QUEST and MSIS-29 scales. Multiple Sclerosis and Related Disorders, 2022, 58, 103495.	2.0	1
3	Dysregulated Gene Expression in Lymphoblasts from Parkinson's Disease. Proteomes, 2022, 10, 20.	3.5	3
4	A 10 year retrospective cohort study of inpatients with youngerâ€onset dementia. International Journal of Geriatric Psychiatry, 2021, 36, 294-301.	2.7	15
5	Characteristics of advanced Parkinson's disease patients seen in movement disorder clinics - Australian results from the cross-sectional OBSERVE study. Clinical Parkinsonism & Related Disorders, 2021, 4, 100075.	0.9	4
6	Mortality in dementia is predicted by older age of onset and cognitive presentation. Australian and New Zealand Journal of Psychiatry, 2021, , 000486742110410.	2.3	9
7	Tractography-Guided Deep Brain Stimulation of the Anteromedial Globus Pallidus Internus for Refractory Obsessive-Compulsive Disorder: Case Report. Neurosurgery, 2020, 86, E558-E563.	1.1	7
8	A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A â€~C-reactive protein' for psychiatrists and neurologists?. Australian and New Zealand Journal of Psychiatry, 2020, 54, 57-67.	2.3	40
9	Functional neuroplasticity in response to cerebello-thalamic injury underpins the clinical presentation of tremor in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 696-705.	3.0	10
10	OCD symptoms in succinic semialdehyde dehydrogenase (SSADH) deficiency: a case report. BMC Psychiatry, 2020, 20, 395.	2.6	4
11	Acoustic Speech Analytics Are Predictive of Cerebellar Dysfunction in Multiple Sclerosis. Cerebellum, 2020, 19, 691-700.	2.5	22
12	OnabotulinumtoxinA treatment for MS-tremor modifies fMRI tremor response in central sensory-motor integration areas. Multiple Sclerosis and Related Disorders, 2020, 40, 101984.	2.0	3
13	Objective measurement in routine care of people with Parkinson's disease improves outcomes. Npj Parkinson's Disease, 2018, 4, 10.	5.3	45
14	The use of accelerometry as a tool to measure disturbed nocturnal sleep in Parkinson's disease. Npj Parkinson's Disease, 2018, 4, 1.	5.3	62
15	What speech can tell us: A systematic review of dysarthria characteristics in Multiple Sclerosis. Autoimmunity Reviews, 2018, 17, 1202-1209.	5.8	79
16	Tremor in multiple sclerosis is associated with cerebello-thalamic pathology. Journal of Neural Transmission, 2017, 124, 1509-1514.	2.8	24
17	Validation of a Smartphone Application Measuring Motor Function in Parkinson's Disease. Journal of Parkinson's Disease, 2016, 6, 371-382.	2.8	44
18	The efficacy of apomorphine – A non-motor perspective. Parkinsonism and Related Disorders, 2016, 33, S28-S35.	2.2	30

ANDREW EVANS

#	Article	IF	CITATIONS
19	Immortalized Parkinson's Disease lymphocytes have enhanced mitochondrial respiratory activity. DMM Disease Models and Mechanisms, 2016, 9, 1295-1305.	2.4	40
20	Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease – Clinical practice recommendations. Parkinsonism and Related Disorders, 2015, 21, 1023-1030.	2.2	126
21	The anteromedial GPi as a new target for deep brain stimulation in obsessive compulsive disorder. Journal of Clinical Neuroscience, 2014, 21, 815-821.	1.5	52
22	Automated Assessment of Bradykinesia and Dyskinesia in Parkinson's Disease. Journal of Parkinson's Disease, 2012, 2, 47-55.	2.8	204
23	A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor. Neurology, 2012, 79, 92-99.	1.1	61
24	Shape alterations in the striatum in chorea-acanthocytosis. Psychiatry Research - Neuroimaging, 2011, 192, 29-36.	1.8	49
25	The neuropsychiatry of neuroacanthocytosis syndromes. Neuroscience and Biobehavioral Reviews, 2011, 35, 1275-1283.	6.1	45
26	The use of a color coded probability scale to interpret smell tests in suspected parkinsonism. Movement Disorders, 2009, 24, 1144-1153.	3.9	34
27	Adolescent obsessive compulsive disorder heralding choreaâ€acanthocytosis. Movement Disorders, 2008, 23, 422-425.	3.9	24
28	[ <sup>123</sup> I] FP IT spect study in vascular parkinsonism and Parkinson's disease. Movement Disorders, 2007, 22, 1278-1285.	3.9	100
29	Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using singleâ€dose challenges. Movement Disorders, 2005, 20, 151-157.	3.9	262